

rTMS Clinical Research Studies Physician Referral form

Location: The Royal's Institute of Mental Health Research (IMHR) Sara Tremblay, PhD, Scientist & IMHR Psychiatrists

The Neuromodulation Unit is looking for participants with treatmentresistant major depressive disorder to take part in our repetitive transcranial magnetic stimulation (rTMS) clinical research studies.

Please note that all referrals are not automatically accepted. Patients will be contacted by telephone and pre-screened for suitability for a consultation with an IMHR rTMS clinic psychiatrist, which will be followed by a screening visit with the study research coordinator to establish if they are eligible to participate in the rTMS study. The IMHR psychiatrist in the rTMS clinic will provide a consultation report with a treatment plan to the referring physician and to the patient's primary care provider.

If your patient suffers from a major depressive episode and you would like them to be assessed for any of our current studies, **please complete the attached referral** form and fax to 613-798-2973. If you have any further questions, please find contact information on the attached form.

Sincerely,

Sara Tremblay, PhD, Study Investigator Neuromodulation Unit

For more information about the study, please contact Stacey Shim at stacey.shim@theroyal.ca 613-722-6521 ext. 6356



Below is a checklist for the consultant to complete:

Inclusion criteria (all criteria must be met)	✓
Male/female, must be ≥ 18 years of age	
Primary or predominant diagnosis of major depressive disorder as a single or recurring episode, without psychotic features	
Depressive symptoms have not improved after ≥ 1 but ≤ 7 adequate dose of antidepressant trial in the current depressive episode	

Exclusion criteria (if one exclusion is checked, the subject is not eligible)	✓
Current or past (< 3 months) substance (excluding caffeine or nicotine) or alcohol abuse/dependence, as defined in DSM-5 criteria. *Exception: prescribed cannabis	
Acute suicidality or threat to life from self-neglect	
Are pregnant or breastfeeding, or thinking of becoming pregnant during course of treatment	
Have a specific contraindication for TMS (e.g., personal history of epilepsy or seizure, metallic head implant, pacemaker)	
*Organic causes to the depressive symptoms (e.g. thyroid dysfunctions) have not been ruled out by the referring physician	

<u>Note:</u> This is not a complete list of inclusion/exclusion criteria. All criteria will be assessed prior to participation in the study. If interested, participants have to agree that their primary physician is informed.

*Baseline investigations for ruling out possible organic causes to be sent to our clinic prior to the patient being scheduled, include:

Complete blood count (CBC)	Thyroid stimulating	Vitamin D – OHIP coverage
and differential	hormone (TSH)	for specific criteria*
Electrolytes, extended electrolytes: Na, K, Calcium, Mg, Phosphate	Fasting Blood Sugar Level (GBSL) and HbA1c	Vitamin B12
Blood Urea Nitrogen and Creatinine (BUN & Cr)	Fasting lipids (cholesterol, triglycerides)	Folic acid
Liver function tests (LFTs)	Iron (ferritin)	Urinalysis

^{*} https://www.health.gov.on.ca/en/public/programs/ohip/changes/docs/MOH_Vitamin_D_FAQ.pdf

Brockville Mental Health Centre

Centre de santé mentale Brockville



PHYSICIAN REFERRAL FOR rTMS TREATMENT

Date of Referral:					
Patient's Name: _	First	Middl	le		Last
E-mail:			Health Card:		
Patient Address:	Street Number 8	k Name	City	Province	Postal Code
Telephone Numb	er: Home: (Mo	bile: ()	
Does the patient	consent to voice	mails at these	numbers?	Yes □ No	o 🗆
Biological Sex:	Female □ Ma	ale 🗆 Othe	er □ D.O.	B.:	
Is the patient's pr	rimary care provi	der (PCP) awa	re of this refe	erral? Yes 🗆	No □
Is the PCP willing and upon dischar		•		ng the rTMS sti Yes □	udy participation No □
	CL	INICAL INF	ORMATION	I	
Has the patient re	eceived brain stin	nulation? 🗆 r	TMS 🗆 MS	ST 🗆 ECT	□ None
If any have been co response achieved,			(i.e. treatment	type, # of treati	ments received, any
What is the patie	nt's primary/pred	ominant mood	l diagnosis?		
☐ Major I	Depressive Disor	der □ Bip	oolar Disorder	☐ Other	

2019-017 Version 5, 4-Apr-2023

These studies have been reviewed and approved by the Royal's IMHR REB **Please fax all completed pages to 613-798-2973.**

1145 avenue Carling Avenue Ottawa ON K1Z 7K4 theroyal.ca / leroyal.ca

Any comorbid diagnoses (ny comorbid diagnoses (i.e. mood/personality/substance use disorders):				
☐ Anxiety			☐ Psychotic Disorder		
\square ADHD			☐ Substance Use Disorder		
\square PTSD			☐ Personality Disorder		
□ OCD			□ Other:		
	ME	DICAL HIST	ORY		
Does the patient have pas	st/current med	ical conditions/i	llnesses/disabilities: Yes \square No \square		
If yes, please indicate detail or surgery received?):	s (i.e. diagnosis,	. start date, has i	t been resolved – if yes, when? Any treatment		
MEDICATIONS/PSYCHOTHERAPY (both psychiatric & non-psychiatric)					
Current	(both psy	chilatric & Hori-	psychiatric)		
Medication Name	Dose	Frequency	Response & Adverse Effects		

1145 avenue Carling Avenue Ottawa ON K1Z7K4 theroyal.ca / leroyal.ca

Tel. / Tél. 613.722.6521 Toll free / Ligne sans frais 1.800.987.6424

Medication Name	Dose	e	Frequency	Response 8	k Adverse Effects
	_				
		-			
	+				
		-+			
				ner:	
If any have been checked	off, please in	ndicate a		ntion and any ben	
	off, please in	ndicate a	details (dates, dura	NCERNS	
f any have been checked	off, please in	ndicate a	& SAFETY CO	NCERNS	efits)
Risk	off, please in	RISKS	& SAFETY CO	NCERNS	efits)
Risk licide Attempt/Ideation Deliberate Self-harm olent Behaviour/Safety Concerns	off, please in	RISKS	& SAFETY CO	NCERNS	efits)
Risk Icide Attempt/Ideation Deliberate Self-harm olent Behaviour/Safety	Yes	RISKS No	& SAFETY CO	NCERNS	efits)

1145 avenue Carling Avenue Ottawa ON K1Z 7K4 theroyal.ca / leroyal.ca Tel. / Tél. 613.722.6521 Toll free / Ligne sans frais 1.800.987.6424

Other Relevant Information:		
REFERRIN	G PHYSICIAN I	NFORMATION
Name:		
First	Middle	Last
Business Number: ()	Phys	Sician #: For OHIP/RAMQ billing
Fax Number: ()		
I confirm that I am the patien		
care, while providing ongoing		
the patient receives treatment notes/recommendations sent		
that the ROMHC is not able to	•	•
	,	3 ,
Signature of Referring Physician	١	Date of Referral (DD/MMM/YYYY)



PATIENT CONSENT FOR E-MAIL COMMUNICATIONS

Dear patient:

By consenting, you will be allowing your care provider and members of the rTMS research team at The Royal Ottawa Mental Health Centre (ROMHC) to communicate with you via e-mail. As with any online platform, it is important that you are aware of the following risks:

- Any inbound/outbound e-mail messages have the potential to be hacked and seen by others using the
 Internet. E-mail security can not be guaranteed as it may be easily forged, accidentally forwarded and may
 exist indefinitely. Thus, it is recommended that you do not use your e-mail to discuss information that you
 deem to be sensitive. If you do consent to e-mail, please let your care provider know if there is any type
 of information that you would prefer not to be discussed via e-mail (for example: test results, medications
 etc.).
- Do not use e-mail for any urgent communications, like in the event of an emergency, as it may not be received/read on time.

Please note:

- Your care provider may make decisions about your care based on information you provided via e-mail.
- If an e-mail has relevant information that is important to your clinical care, it may be copied/summarized into your medical record similar to any phone communications.
- E-mails containing information relevant to your care, may be forwarded or read by other ROMHC staff members on an as needed basis. Your care provider will inform you if another person will read/respond to your e-mail on their behalf.

By providing your consent, we may use e-mail to communicate with you or your delegated person(s) outside the hospital.

You have the right to withdraw your consent to e-mail communications at any time, just let your care provider know as soon as possible.

By signing below, you consent to e-mail communications and its associated risks.				
IPrint Name	_, hereby consent to the ROMHC group to:			
☐ Communicate with me by e-mail at:				
,	E-mail Address			
☐ Communicate with	, Relationship:			
Delegated Person's Name				
at:				
E-mail Address				
☐ Communicate with the following outside care providers by e-mail:				
Patient Signature	Signature Date (DD/MMM/YYYY)			